42 results about "Cornea dystrophy" patented technology

The invention provides a wearable device for delivery of light of a desired wavelength and power to the cornea of a subject. The device includes a frame for attachment of a light source housing which includes a light source and a lens positioned in the housing to allow light to be directed to the eye of the subject, and the light source is operably linked to a power source. The invention provides method for the prevention and treatment of ocular disease including infection, neoplasia, and corneal dystrophies. The device of the invention can be used in conjunction with photoactive therapeutic agents.

The present invention relates to a pharmaceutical agent for treating Avellino corneal dystrophy, and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy comprising pharmaceutically effective amount of blood plasma or serum as an active ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms by dissolving away hyaline granules in the cornea of a patient with severe Avellino corneal dystrophy due to LASIK surgery.

The present invention relates to oligonucleotides for diagnosis of corneal dystrophy. More particularly, the present invention relates to oligonucleotides for detecting mutation of BIGH3 gene for diagnosis of corneal dystrophy including Avelllino corneal dystrophy, which must be precisely diagnosed before vision correction surgery, and a DNA chip for diagnosis of corneal dystrophy, which has the oligonucleotides fixed thereon. According to the present invention, conventional microscopic diagnosis of corneal dystrophy can be replaced with a precise genetic method, which prevents a patient with corneal dystrophy from losing eyesight by eyesight correction surgery after erroneous diagnosis.

The present invention relates to oligonucleotides for diagnosis of corneal dystrophy. More particularly, the present invention relates to oligonucleotides for detecting mutation of BIGH3 gene for diagnosis or corneal dystrophy including Avellino corneal dystrophy, which must be precisely diagnosed before vision correction surgery, and a DNA chip for diagnosis of corneal dystrophy, which has the oligonucleotides fixed thereon. According to the present invention, conventional microscopic diagnosis of corneal dystrophy can be replaced with a precise genetic method, which prevents a patient with corneal dystrophy from losing eyesight by eyesight correction surgery after erroneous diagnosis.

The present invention relates to a real-time PCR primer pair and probe for diagnosing Avellino corneal dystrophy, and more particularly to a real-time PCR primer pair and probe for diagnosing Avellino corneal dystrophy, which can accurately diagnose the presence or absence of a mutation in exon 4 of BIGH3 gene, which is responsible for Avellino corneal dystrophy. The use of the primer pair and probe according to the invention can diagnose Avellino corneal dystrophy in a more rapid and accurate manner than a conventional method that uses a DNA chip or PCR.

The present invention relates to a system for diagnosing Avellino corneal dystrophy, and more particularly to a system for diagnosing Avellino corneal dystrophy, in which whether a sample is normal or Avellino corneal dystrophy is determined based on the ratio of the input first PCR amplification value and the second PCR amplification value. The system makes it possible to diagnosis Avellino corneal dystrophy in a simpler and accurate manner without being influenced by the doctor's skill. Particularly, the inventive system makes the overall process systematic, and thus provides accurate diagnosis. In addition, the system can also easily administer a number of test subjects.

Systems and methods for detecting at least two genomic alleles associated with corneal dystrophy in a sample from a human subject are disclosed in which cells (e.g., epithelial) of the subject are adhered to a tip of a substrate. The tip of the substrate is agitated in a lysis solution that lyses cells adhered to the substrate. The substrate is removed from the lysis solution upon completion of this agitation. The resulting lysis solution is incubated and then genomic DNA from the lysis solution is isolated to form a gDNA solution. From this, identity of at least two nucleotides present in the human TGFpI gene is determined using at least two oligonucleotide primer pairs and the gDNA solution. These at least two nucleotides are located at respective independent positions of the TGFpI gene corresponding to respective independent single nucleotide polymorphisms (SNPs) associated with corneal dystrophy.

The invention discloses a method for detecting a genotype of polymorphic sites of a corneal dystrophy gene and its kit. In a same reaction system, real-time fluorescence quantification PCR detection is respectively carried out on a same to-be-detected sample by an enhanced ARMS primer aiming at a gene wild type template for polymorphic sites of corneal dystrophy and an enhanced ARMS primer aimingat a mutant template; according to a Ct mutant type detected by the real-time fluorescence quantification detection by the enhanced ARMS primer aiming at the gene wild type template, a Ct wild type detected by the real-time fluorescence quantification detection by the enhanced ARMS primer aiming at the mutant template, and a difference delta-Ct value of the Ct mutant type and the Ct wild type, and the mutant genotype of the corneal dystrophy gene can be determined according to the types of the polymorphic site. The method has the advantages of simple operation and high accuracy.

A multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing corneal dystrophy, and more particularly to a multi-spot metal-capped nanostructure array nucleic acid chip capable of employing LSPR (localized surface plasmon resonance) optical properties, a preparation method thereof, and a multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing BIGH3 gene mutations, which can diagnose various corneal dystrophies. The metal-capped nanostructure array nucleic acid chip can be combined with analysis devices, including a light source, a detector, a spectrophotometer and a computer, to provide an LSPR optical property-based optical biosensor, and the use of the multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing BIGH3 gene mutations allows the simultaneous diagnosis of various corneal dystrophies that are genetic ocular diseases.

The invention relates to a method for analyzing pathogenesis of cornea related diseases, and belongs to the field of biomedical technologies. Specifically, the invention relates to a method for recognizing and analyzing the pathogenesis of the cornea related diseases at a nanometer scale by using a specific instrument. According to the invention, an auxiliary analysis method for the pathogenesis of the cornea related diseases is provided from such two aspects as morphology and related mechanical properties at the nanometer scale by using a quantitative nanomechanics atomic force microscope, and detailed elaboration is conducted by taking a Fuchs endothelial cornea dystrophy disease as an example, thereby providing the universality of the method in cornea related disease research.

The invention provides a primer probe for diagnosing corneal dystrophy caused by mutation of a site 124 of a human TGFbetaI gene. The primer probe comprises a specific primer designed for the site 124of the TGFbetaI gene, a specific wild type Taqman fluorescent probe for a wild type site R124, and at least one of four specific mutation type Taqman fluorescent probes for mutation type sites C124,S124, H124 and L124, wherein each probe is connected with a different fluorescent report group, so as to collect different fluorescent signals to detect, and internal references are not added. The invention further provides a primer probe-based detection method for mutation of the site 124 of the human TGFbetaI gene. The detection method has advantages of being highly sensitive, highly specific, being not easy to contaminate, being highly accurate, and being convenient and quick, and is applicable to clinical case analysis and inspection work.

The invention relates to an application of BIGH3 in preparation of an animal model with corneal dystrophy. The corneal dystrophy model with stability in genetics and stability in phenotype is established, and the model is realized by mutating the 124th site of a Bigh3 protein of a non-human mammalian from Arg to His. By taking the transgenic animal model provided by the invention as a research model, the feasibility of preventing and treating corneal dystrophy diseases can be investigated on the gene level, and a research basis is provided for gene diagnosis and treatment of granular corneal dystrophy.

The invention provides a human TGFBI gene mutation detection kit and a detection method thereof. The invention provides effective and targeted protection at an early stage for carriers of a corneal abnormality mutation gene, and can delay the development of a disease course and even avoid the onset of a disease. The invention provides a primer and a probe for detecting corneal dystrophy caused bymutation of a human TGFBI gene at a 124-site and a 555-site, and the primer and the probe are capable of detecting the mutation of the TGFBI gene at the 124-site and the 555-site, high in sensitivityand strong in specificity. The invention provides the corneal abnormality mutation gene detection kit which is capable of rapidly, efficiently and accurately detecting the mutation of the human TGFBIgene at the 124-site and the 555-site. The invention further provides the detection method for detecting the mutation of the human TGFBI gene at the 124-site and the 555-site by the kit, and the detection method has the advantages of simple operation, high sensitivity, high specificity, wide application models, true and reliable detection results, easy promotion and the like.

The invention relates to the field of medicine, in particular to oligonucleotide, a virus vector, application of the oligonucleotide or the virus vector, and an RNAi medicinal preparation. The oligonucleotide is one of sequences from SEQ ID NO: 4 to SEQ ID NO: 40; or a nucleic acid sequence having no less than 80% consistency with one of the sequences from SEQ ID NO: 4 to SEQ ID NO: 40. The oligonucleotide, the virus vector and the RNAi medicinal preparation provided by the invention can effectively treat and prevent corneal dystrophy caused by COL8A2 mutation.

The invention provides a plaque corneal dystrophy animal model, a construction method of a gene therapy vector and a delivery system, and relates to the technical field of model construction. According to the animal model, animal Chst5 genes are knocked out from corneal endothelium in an anterior chamber injection mode or through Chst5R50H point mutation, and compared with an existing animal model, the eye symptom similarity is higher. The invention also provides a gene therapy vector which is realized by injecting the adeno-associated virus vector into the anterior chamber to carry the wild type mouse Chst5 gene. In the embodiment of the invention, the treatment of plaque corneal dystrophy can be realized by injecting the gene therapy vector into the anterior chamber of the mouse model.

Methods and compositions for the treatment of a corneal dystrophy in a subject in need thereof are provided. In one aspect, the method includes the step of obtaining a plurality of stem cells comprising a nucleic acid mutation in a corneal dystrophy target nucleic acid from the subject and manipulating the nucleic acid mutation in one or more stem cells of the plurality of stem cells to correct the nucleic acid mutation, thereby forming one or more manipulated stem cells. The manipulated stem cells are isolated and then transplanted into the subject. In some embodiments, the nucleic acid mutation is manipulated using CRISPR system.

The invention relates to the technical field of biological medicines, and discloses oligonucleotide and an application thereof. The oligonucleotide is a nucleotide of which the consistency with any one of nucleotide sequences shown in SEQ ID NO: 1 to SEQ ID NO: 20 is not lower than 80%. The invention proves that the oligonucleotide targeting the intron 2 of the TCF4 gene is used as RNAi drug to treat, so that the aggregation of the mutated toxic intron RNA of the TCF4 can be obviously reduced, but the mRNA and protein expression of the normal TCF4 are not obviously influenced. The RNAi drug treatment provided by the invention can relieve corneal dystrophy caused by RNA aggregation and accumulation due to TCF4 mutation, moreover, the RNAi medicine not only can prevent deterioration of corneal dystrophy caused by TCF4 mutation, but also can play a role in preventing diseases caused by TCF4 mutation.